346 related articles for article (PubMed ID: 11239793)
61. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
62. New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
Undas A; Celińska-Löwenhoff M; Kaczor M; Musial J
Thromb Haemost; 2004 Jun; 91(6):1065-77. PubMed ID: 15175791
[TBL] [Abstract][Full Text] [Related]
63. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
[TBL] [Abstract][Full Text] [Related]
64. [HMG-CoA reductase inhibitor and risk of stroke].
Endres M; Laufs U
Nervenarzt; 1998 Aug; 69(8):717-21. PubMed ID: 9757426
[TBL] [Abstract][Full Text] [Related]
65. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.
Arnaud C; Veillard NR; Mach F
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):127-34. PubMed ID: 15853754
[TBL] [Abstract][Full Text] [Related]
66. Effects of statins on endothelium and signaling mechanisms.
Endres M; Laufs U
Stroke; 2004 Nov; 35(11 Suppl 1):2708-11. PubMed ID: 15375300
[TBL] [Abstract][Full Text] [Related]
67. Pleiotropic effects of statins: moving beyond cholesterol control.
Garcia PJ
Curr Atheroscler Rep; 2005 Feb; 7(1):34-9. PubMed ID: 15683600
[TBL] [Abstract][Full Text] [Related]
68. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
69. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.
Sawada N; Liao JK
Antioxid Redox Signal; 2014 Mar; 20(8):1251-67. PubMed ID: 23919640
[TBL] [Abstract][Full Text] [Related]
70. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
71. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Davidson MH
Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
[TBL] [Abstract][Full Text] [Related]
72. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome.
Sowers JR
Am J Cardiol; 2003 Feb; 91(4A):14B-22B. PubMed ID: 12615294
[TBL] [Abstract][Full Text] [Related]
73. Statin therapy for coronary heart disease and its effect on stroke.
Switzer JA; Hess DC
Curr Atheroscler Rep; 2006 Jul; 8(4):337-42. PubMed ID: 16822401
[TBL] [Abstract][Full Text] [Related]
74. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
Tschudi MR; Noll G; Lüscher TP
Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
[TBL] [Abstract][Full Text] [Related]
75. Clinical implications for statin pleiotropy.
Liao JK
Curr Opin Lipidol; 2005 Dec; 16(6):624-9. PubMed ID: 16276239
[TBL] [Abstract][Full Text] [Related]
76. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells.
Skaletz-Rorowski A; Lutchman M; Kureishi Y; Lefer DJ; Faust JR; Walsh K
Cardiovasc Res; 2003 Jan; 57(1):253-64. PubMed ID: 12504836
[TBL] [Abstract][Full Text] [Related]
77. Beneficial cardiovascular pleiotropic effects of statins.
Davignon J
Circulation; 2004 Jun; 109(23 Suppl 1):III39-43. PubMed ID: 15198965
[TBL] [Abstract][Full Text] [Related]
78. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Endres M; Laufs U; Huang Z; Nakamura T; Huang P; Moskowitz MA; Liao JK
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8880-5. PubMed ID: 9671773
[TBL] [Abstract][Full Text] [Related]
79. Pleiotropic Benefits of Statins in Cardiovascular Diseases.
Wasim R; Ansari TM; Ahsan F; Siddiqui MH; Singh A; Shariq M; Parveen S
Drug Res (Stuttg); 2022 Nov; 72(9):477-486. PubMed ID: 35868336
[TBL] [Abstract][Full Text] [Related]
80. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
